Apellis Pharmaceuticals マネジメント

マネジメント基準チェック /24

Apellis Pharmaceuticalsの CEO はCedric Francoisで、 Sep2009年に任命され、の在任期間は 15.17年です。の年間総報酬は$ 10.37Mで、 7.1%給与と92.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.38%を直接所有しており、その価値は$ 52.65M 。経営陣と取締役会の平均在任期間はそれぞれ5.8年と9.3年です。

主要情報

Cedric Francois

最高経営責任者

US$10.4m

報酬総額

CEO給与比率	7.1%
CEO在任期間	15.2yrs
CEOの所有権	1.4%
経営陣の平均在職期間	5.8yrs
取締役会の平均在任期間	9.3yrs

経営陣の近況

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Recent updates

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Jul 12

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Jul 19

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

May 13

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Apr 18

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?

Dec 14

CEO報酬分析

Apellis Pharmaceuticals の収益と比較して、Cedric Francois の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$250m
Jun 30 2024	n/a	n/a	-US$333m
Mar 31 2024	n/a	n/a	-US$417m
Dec 31 2023	US$10m	US$735k	-US$529m
Sep 30 2023	n/a	n/a	-US$606m
Jun 30 2023	n/a	n/a	-US$657m
Mar 31 2023	n/a	n/a	-US$691m
Dec 31 2022	US$9m	US$681k	-US$652m
Sep 30 2022	n/a	n/a	-US$634m
Jun 30 2022	n/a	n/a	-US$638m
Mar 31 2022	n/a	n/a	-US$702m
Dec 31 2021	US$9m	US$647k	-US$746m
Sep 30 2021	n/a	n/a	-US$520m
Jun 30 2021	n/a	n/a	-US$460m
Mar 31 2021	n/a	n/a	-US$360m
Dec 31 2020	US$9m	US$619k	-US$345m
Sep 30 2020	n/a	n/a	-US$536m
Jun 30 2020	n/a	n/a	-US$470m
Mar 31 2020	n/a	n/a	-US$423m
Dec 31 2019	US$4m	US$560k	-US$305m
Sep 30 2019	n/a	n/a	-US$228m
Jun 30 2019	n/a	n/a	-US$194m
Mar 31 2019	n/a	n/a	-US$156m
Dec 31 2018	US$4m	US$550k	-US$128m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$85m
Mar 31 2018	n/a	n/a	-US$64m
Dec 31 2017	US$2m	US$400k	-US$51m

報酬と市場: Cedricの総報酬 ($USD 10.37M ) は、 US市場 ($USD 6.56M ) の同規模の企業の平均を上回っています。

報酬と収益: Cedricの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Cedric Francois (52 yo)

15.2yrs

在職期間

US$10,373,049

報酬

Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Cedric Francois	Co-Founder	15.2yrs	US$10.37m	1.38% $ 52.7m
Alec Machiels	Co-Founder & Director	15.8yrs	US$495.96k	0.62% $ 23.9m
Timothy Sullivan	CFO & Treasurer	7.1yrs	US$3.74m	0.082% $ 3.1m
Adam Townsend	Chief Operating Officer	less than a year	US$3.71m	0.023% $ 869.2k
David Watson	General Counsel	10.8yrs	US$4.89m	0.092% $ 3.5m
Caroline Baumal	Chief Medical Officer	1.8yrs	US$4.43m	0.0050% $ 192.9k
Pascal Deschatelets	Co-Founder & Chief Scientific Officer	15.2yrs	US$3.08m	0.90% $ 34.3m
James Chopas	VP, Corporate Controller & Chief Accounting Officer	3.3yrs	データなし	0.0097% $ 372.8k
Meredith Kaya	Senior Vice President	no data	データなし	データなし
Karen Lewis	Chief People Officer	4.5yrs	データなし	0.00071% $ 27.2k
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	2.5yrs	データなし	データなし
Victoria Brown	Senior Vice President	5.8yrs	データなし	データなし

5.8yrs

平均在職期間

51.5yo

平均年齢

経験豊富な経営陣: APLSの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Cedric Francois	Co-Founder	15.2yrs	US$10.37m	1.38% $ 52.7m
Alec Machiels	Co-Founder & Director	15.2yrs	US$495.96k	0.62% $ 23.9m
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	9.3yrs	データなし	データなし
Lokchung L. Chan	Independent Chairman of the Board	11.3yrs	US$504.08k	0.00054% $ 20.7k
Stephanie O'Brien	Independent Director	11.3yrs	US$488.46k	0.00054% $ 20.7k
Gabriel Coscas	Member of AMD Scientific Advisory Board	9.3yrs	データなし	データなし
Robert Brodsky	Member of PNH Scientific Advisory Board	9.3yrs	データなし	データなし
Michael Yeadon	Member of Pulmonology Scientific Advisory Board	9.3yrs	データなし	データなし
Paul Fonteyne	Independent Director	4.6yrs	US$489.08k	0.0046% $ 174.5k
A. Dunlop	Independent Director	14.7yrs	US$480.96k	0.12% $ 4.5m
Marsha Wills-Karp	Member of Pulmonology Scientific Advisory Board	no data	データなし	データなし
Carl Atkinson	Member of Pulmonology Scientific Advisory Board	9.3yrs	データなし	データなし

9.3yrs

平均在職期間

57.5yo

平均年齢

経験豊富なボード: APLSの取締役会は経験豊富であると考えられます ( 9.3年の平均在任期間)。

Apellis Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Independent Director notifies of intention to sell stock

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Recent updates

Consensus EPS estimates fall by 24%

Price target decreased by 18% to US$51.79

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Apellis Pharmaceuticals, Inc. Presents Positive Results from the Phase 3 VALIANT Study at Kidney Week

Price target decreased by 7.0% to US$63.11

Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?

Forecast breakeven date pushed back to 2026

Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion

Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Price target decreased by 7.6% to US$69.12

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 11%

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Independent Director notifies of intention to sell stock

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Consensus EPS estimates fall by 17%

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 18%

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Consensus EPS estimates upgraded to US$0.98 loss

Consensus EPS estimates upgraded to US$1.00 loss

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Technical Operations Officer recently sold US$646k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Co-Founder notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold US$525k worth of stock

Price target increased by 9.0% to US$71.44

Price target decreased by 9.6% to US$66.69

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

CFO & Treasurer exercised options and sold US$633k worth of stock

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Price target decreased by 9.8% to US$93.23

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

New minor risk - Share price stability

General Counsel notifies of intention to sell stock

Chief People Officer notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

マネジメント基準チェック /24